Subject: Last chance to register for today's webinar on managing IBS nutritionally
![]() |
||
View this email in a browser | Update your information | ||
![]() |
||
![]() |
||
On Thursday, June 28, 2018, from 2–3 PM EDT, Kate Scarlata, RDN, LDN, and William Chey, MD, FACG, AGAF, FACP, RFF, will discuss how Irritable bowel syndrome (IBS) is a complex, heterogeneous gastrointestinal disorder that impacts 40–45 million Americans. As there is growing interest in nutritional approaches for IBS symptom management, dietitians should understand how diet may impact functional gut symptoms as well as apply a low FODMAP diet when working with this population. As an evolving nutritional approach, up to date food composition and the latest research will be reviewed. Learning Objectives After completing this continuing education course, nutrition professionals should be able to:
|
||
|
||
|
||
About Our Presenters
His research interests focus on the diagnosis & treatment of functional bowel disorders and H. pylori infection. He is a medical innovator and holds 3 patents. He co-founded “My Total Health” (https://mygihealth.io), a company developing novel health information technology solutions for persons with GI problems. Dr Chey has authored more than 300 manuscripts, reviews, chapters & books. Dr. Chey is a member of the Board of Trustees of the American College of Gastroenterology, Board of Directors of the Rome Foundation, and Council of the American Neurogastroenterology & Motility Society. He is Chief Scientific Advisor for the International Foundation of Functional GI Disorders. He has been elected to “Best Doctors” since 2001 and received the Dean’s Outstanding Clinician Award at the University of Michigan and the Distinguished Clinician Award from the American Gastroenterological Association. Disclosures Kate Scarlata, RDN, LDN, reports the following relevant disclosures: She has received consultant fees from Fody Foods and Casa de Sante and receives other financial support from FODMAP books and iTunes. Dr. Chey reports the following relevant disclosures: He has received grants, research support, consultant fees and/or honoraria from Ironwood, BioMedica, Vibrant, Allergan, Zespri, Outpost, Salix/Valeant, Shire, and Ritter. Both have certified that no conflict of interest exists for this program. View our disclosure policy. |